Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immunovant, Inc. - Common Stock (NQ: IMVT )

20.33 +0.47 (+2.37%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,241,035
Open 19.99
Bid (Size) 19.87 (2)
Ask (Size) 20.47 (2)
Prev. Close 19.86
Today's Range 19.89 - 20.49
52wk Range 19.07 - 39.55
Shares Outstanding 114,998,871
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
High Frequency Trading, PPI Misreads Helped Fuel a Short Squeeze... Now What
With inflation and jobs behind us, it’s time to shift our focus 6,700 miles west to Tokyo. The Bank of Japan appears poised for another rate hike next week, with odds now at 77%. Monitor the VIX for... 
Via Talk Markets
Topics Economy Stocks
Exposures Interest Rates US Equities
Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases
Amgen tested its drug, Uplizna, in generalized myasthenia gravis, a market where Argenx's Vyvgart leads. 
Via Investor's Business Daily

Performance

YTD
-19.29%
-19.29%
1 Month
-14.58%
-14.58%
3 Month
-20.31%
-20.31%
6 Month
-34.78%
-34.78%
1 Year
-45.26%
-45.26%

More News

Read More
Four Stocks To Watch This Week - Monday, Sep. 23
Via Talk Markets
What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?
Via Benzinga
Top 2 Health Care Stocks That May Collapse This Quarter
Via Benzinga
Recap: Immunovant Q3 Earnings
Via Benzinga
Roivant Provides Update on Graves’ Disease Development Program
From Roivant Sciences
Via GlobeNewswire
After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay
Via Investor's Business Daily
IMVT Stock Earnings: Immunovant Misses EPS for Q4 2024
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Biohaven Stock Stumbles As Protein-Degrading Drug Falls Short Of Expectations In Early-Stage Study
Via Benzinga
Why Bank of Montreal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Heico Posts Upbeat Earnings, Joins Surmodics, Abercrombie & Fitch And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Biohaven Crashes After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump
Via Investor's Business Daily
Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich
Via InvestorPlace
Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results
Via Investor's Business Daily
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024
Via InvestorPlace
7 Russell 2000 Stocks to Buy for the Next Bull Run: February 2024
Via InvestorPlace
3 Top-Rated Russell 2000 Stocks Wall Street Analysts Are Loving Now: January 2024
Via InvestorPlace
5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond
Via The Motley Fool
Stock Market Rally Is In Merry Mood Heading Into Christmas Weekend: Weekly Review
Via Investor's Business Daily
Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Immunovant Scores Much-Needed Win Following Argenx-Led Sell-off
Via Investor's Business Daily
Autoimmune Disease Player Immunovant's Investigational Drug For Immune System Disorder Shows Response Rates Of Over 50%
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.